Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ortek Therapeutics

This article was originally published in The Tan Sheet

Executive Summary

Garden City, N.Y. firm to begin a U.S. trial by year end examining the effects of Cavistat on xerostomia (dry mouth) induced caries. Cavistat, which Ortek licenses from the State University of New York at Stonybrook, is a patented combination of arginine, calcium and a "cariostatic anion" thought to remineralize teeth. Ortek may launch a dentifrice containing the ingredient next year; the firm also is exploring marketing partnerships with larger companies. A 12-week, 100-subject trial already has been conducted showing Cavistat to be effective in treating tooth sensitivity, and another 750-subject caries study taking place in South America is scheduled to be completed in roughly a year

Topics

UsernamePublicRestriction

Register

PS091158

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel